Drug induced fatty liver disease (DIFLD) is a form of drug-induced liver injury (DILI), which
can also be included in the more general metabolic dysfunction-associated steatotic liver …

Metabolic dysfunction-associated fatty liver disease (commonly known as MAFLD) impacts
global health in epidemic proportions, and the resulting morbidity, mortality and economic …

Background Nonalcoholic fatty disease (NAFLD) is the most common liver disease, since it
is strongly associated with obesity and metabolic syndrome pandemics. NAFLD may affect …

Drug-induced liver injury (DILI) is a common and underestimated cause of liver disease.
Several drugs and other xenobiotics can be the cause of different clinicopathologic patterns …

Drug-induced steatosis (DIS) and drug-induced steatohepatitis (DISH) are two of several
types of drug-induced liver injury (DILI). They can be caused by various drugs and may …

Drug-induced liver injury (DILI) poses a complex and heterogeneous clinical challenge,
which often resembles non-drug related acute or chronic liver diseases, such as metabolic …

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver disease in developed
countries. Its frequency is increasing in the general population mostly due to the widespread …

Drug-induced fatty liver disease (DIFLD) covers a group of adverse drug reactions whose
prevalence accounts for about 10% of all adverse reactions. The aim of this review was to …

Over the past decades, many drugs have been identified, that can potentially induce
steatohepatitis in the predisposed individual. Classically this has been incriminated to …

Metabolic-associated fatty liver disease (MAFLD), which is often linked to obesity,
encompasses a large spectrum of hepatic lesions, including simple fatty liver …